Gemeinsamer Bundesausschuss

Resolution

of the Federal Joint Committee (G-BA) on the Suspension of the Benefit Assessment pursuant to Section 35a SGB V of Idecabtagene Vicleucel (reassessment of an orphan drug after exceeding the EUR 30 million turnover limit; multiple myeloma, at least 3 prior therapies)

of 2 May 2024

The Federal Joint Committee (G-BA) decided the following at its session on 2 May 2024:

Due to the benefit assessment procedure on idecabtagene vicleucel in the therapeutic indication multiple myeloma after at least 2 prior therapies, which was initiated on 1 April 2024 in accordance with Section 35a, paragraph 1 SGB V, and which comprises both the question to patients after at least 3 prior therapies (exceeding the € 30 million turnover limit) and the question to patients with two prior therapies (new therapeutic indication), the benefit assessment procedure on idecabtagene vicleucel in the therapeutic indication multiple myeloma after at least 3 prior therapies separately, started on 1 March 2024, is suspended.

The justification to this resolution will be published on the website of the G-BA at www.g-ba.de.

Berlin, 2 May 2024

Federal Joint Committee (G-BA)
in accordance with Section 91 SGB V
The Chair

Prof. Hecken